The EFEMP1 Knockout A2780 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed for studying EFEMP1 (fibulin-3) loss-of-function in the context of human ovarian adenocarcinoma. This polyclonal model offers a heterogeneous knockout background, enabling robust analysis of gene function without the biases of monoclonal selection. Disruption of the EFEMP1 gene in these A2780 cells provides a valuable tool for investigating the gene’s role in extracellular matrix biology and cancer progression.
The host A2780 cell line is a widely utilized epithelial ovarian cancer model originally derived from a patient with endometrioid adenocarcinoma. A2780 cells are characterized by their adherent epithelial morphology and their utility in studying ovarian cancer cell behavior, including proliferation, migration, invasion, and drug response. This well-established line is particularly relevant for research into metastasis and chemoresistance, making it an appropriate background for interrogating the function of ECM-related genes like EFEMP1.
EFEMP1 encodes fibulin-3, a secreted extracellular matrix glycoprotein that interacts with multiple structural and signaling molecules. Fibulin-3 is known to bind integrin receptors, particularly integrin alpha5/beta1, and the tissue inhibitor of metalloproteinases TIMP3, modulating focal adhesion dynamics and ECM turnover. Through these interactions, EFEMP1 influences downstream signaling cascades, including PI3K/AKT and MAPK/ERK pathways, and regulates the expression of matrix metalloproteinases such as MMP2 and MMP9. Upstream regulators like TGF-?? and HIF-1?? transcriptionally control EFEMP1 expression, while its downstream effects impinge on epithelial-mesenchymal transition markers, including Vimentin and E-cadherin. In the knockout cells, loss of fibulin-3 disrupts integrin-ECM crosstalk, leading to altered phosphorylation of AKT and ERK1/2, and dysregulated MMP activity, which collectively remodel the cellular response to extracellular cues.
In the A2780 ovarian cancer model, EFEMP1 knockout has profound implications for tumor cell adhesion, migration, and invasion. Fibulin-3 loss compromises ECM integrity and cell-matrix interactions, potentially enhancing metastatic competence by disrupting the balance between MMPs and their inhibitors. This model is particularly valuable for studying the tumor microenvironment, as EFEMP1 is implicated in ovarian cancer progression and may influence chemosensitivity through signaling pathways such as TGF-??/SMAD and PI3K/AKT. Researchers can employ this polyclonal knockout population to dissect the contribution of fibulin-3 to cancer cell plasticity and the acquisition of invasive phenotypes.
Typical applications include functional assays such as wound healing and Transwell migration/invasion to assess cell motility, as well as biochemical analyses of ECM components and signaling intermediates via Western blotting and co-immunoprecipitation. Expression profiling of MMP2, MMP9, and EMT markers by qRT-PCR further illuminates the molecular consequences of EFEMP1 depletion. These cells serve as a versatile platform for drug sensitivity screens, especially those targeting ECM-integrin signaling or PI3K/AKT and MAPK cascades, and for studies of tumor-stroma interactions. For additional technical specifications and pricing, please contact Ascent Research.
